ELSY BOGLIOLI

Corporate Board Profile

Tech Score: 0/100

FTI CONSULTING, INC

Filing Date	Source Excerpt
2023-04-24	Elsy Boglioli is the founder and has been Chief Executive Officer of Bio-Up, a consulting firm providing advisory services to companies in the healthcare technology field, since September 2019. From December 2017 to August 2019, Ms. Boglioli was Executive Vice President and Chief Operating Officer of Cellectis, a clinical-stage biopharmaceutical company focusing on cell therapies. Ms. Boglioli has extensive experience in the consulting services industry, having been employed by the Boston Consulting Group, a leading business strategy consulting services firm, from January 2006 to November 2017, holding various positions, including Partner and Managing Director and leader of its biotech-focused business in Europe, and serving as a member of its global Strategy and Biopharma Practice leadership teams. ... Current Foreign Public Company Directorships and Committees: GenSight Biologics S.A. [Chair of the Nomination Committee] OSE Immunotherapeutics SA [Member of the Nomination and Remuneration Committee] ... On April 6, 2023, the Board took action, and effective on April 7, 2023, the size of the Board was increased to ten directors from nine directors and the Board elected Elsy Boglioli as a director to fill the vacancy on the Board resulting from such action. The Board has not taken action to elect Ms. Boglioli to any Committee.
2024-04-19	Elsy Boglioli is the founder and has been Chief Executive Officer of Bio-Up, a consulting firm providing advisory services to companies in the healthcare technology field, since September 2019. From December 2017 to August 2019, Ms. Boglioli was Executive Vice President and Chief Operating Officer of Cellectis, a clinical-stage biopharmaceutical company focusing on cell therapies. Ms. Boglioli has extensive experience in the consulting services industry, having been employed by The Boston Consulting Group, a leading business strategy consulting services firm, from January 2006 to November 2017, holding various positions, including Partner and Managing Director and leader of its biotech-focused business in Europe, and serving as a member of its global Strategy and Biopharma Practice leadership teams. Other Foreign Public Company Directorships and Committees: GenSight Biologics S.A. [Chair of Nominating Committee], OSE Immunotherapeutics SA [Member of Nominating and Remuneration Committee]. 2023 Non-Employee Directors: Elsy Boglioli 57,671 Annual Retainer and 288,102 Stock Awards totaling 345,773.

Filing Date

Source Excerpt

2023-04-24

Elsy Boglioli is the founder and has been Chief Executive Officer of Bio-Up, a consulting firm providing advisory services to companies in the healthcare technology field, since September 2019. From December 2017 to August 2019, Ms. Boglioli was Executive Vice President and Chief Operating Officer of Cellectis, a clinical-stage biopharmaceutical company focusing on cell therapies. Ms. Boglioli has extensive experience in the consulting services industry, having been employed by the Boston Consulting Group, a leading business strategy consulting services firm, from January 2006 to November 2017, holding various positions, including Partner and Managing Director and leader of its biotech-focused business in Europe, and serving as a member of its global Strategy and Biopharma Practice leadership teams. ... Current Foreign Public Company Directorships and Committees: GenSight Biologics S.A. [Chair of the Nomination Committee] OSE Immunotherapeutics SA [Member of the Nomination and Remuneration Committee] ... On April 6, 2023, the Board took action, and effective on April 7, 2023, the size of the Board was increased to ten directors from nine directors and the Board elected Elsy Boglioli as a director to fill the vacancy on the Board resulting from such action. The Board has not taken action to elect Ms. Boglioli to any Committee.

2024-04-19

Elsy Boglioli is the founder and has been Chief Executive Officer of Bio-Up, a consulting firm providing advisory services to companies in the healthcare technology field, since September 2019. From December 2017 to August 2019, Ms. Boglioli was Executive Vice President and Chief Operating Officer of Cellectis, a clinical-stage biopharmaceutical company focusing on cell therapies. Ms. Boglioli has extensive experience in the consulting services industry, having been employed by The Boston Consulting Group, a leading business strategy consulting services firm, from January 2006 to November 2017, holding various positions, including Partner and Managing Director and leader of its biotech-focused business in Europe, and serving as a member of its global Strategy and Biopharma Practice leadership teams. Other Foreign Public Company Directorships and Committees: GenSight Biologics S.A. [Chair of Nominating Committee], OSE Immunotherapeutics SA [Member of Nominating and Remuneration Committee]. 2023 Non-Employee Directors: Elsy Boglioli 57,671 Annual Retainer and 288,102 Stock Awards totaling 345,773.

Data sourced from SEC filings. Last updated: 2026-02-03